In September 2024, the FDA announced that five peptide bulk drug substancesincluding Thymosin Alpha-1 (TA-1), CJC-1295, Ipamorelin, Pentadecapeptide, and Selank Nasalwere removed from the Category 2 list due to a change in the substances nomination status22source23source
Dureau P, Broyer M, Dufier JL (2003) Evolution of ocular manifestations in nephropathic cystinosis: a long-term study of a population treated with cysteamine
The future of weight loss medication coverage Coverage for weight loss treatments is expected to change, particularly as studies demonstrate that treating obesity can result in lower long-term healthcare costs
Advertisement Tests to diagnose dumping syndrome include: Advertisement Most people can successfully manage dumping syndrome with dietary changes
Proactive hydration strategies can help patients taking GLP-1 receptor agonists maintain adequate fluid balance and minimize thirst-related discomfort
While a simple calendar can suffice, smartphone apps are also available for this purpose